Last reviewed · How we verify
NCT03811379
Toripalimab as Monotherapy for Patients With Small Cell Carcinoma of Esophagus Who Failed Chemotherapy
Status unknown
Phase 2
Last updated 23 January 2019
What this trial tests
Phase 2 trial testing Toripalimab in Small Cell Carcinoma of Esophagus in 43 participants. Status unknown.
Timeline
21 November 2018
Primary endpoint
30 December 2020
30 December 2020
30 December 2021
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 43 |
| Start date | 21 November 2018 |
| Primary completion | 30 December 2020 |
| Estimated completion | 30 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Toripalimab (TORIPALIMAB) — full drug profile →
Conditions studied
- Small Cell Carcinoma of Esophagus — all drugs for Small Cell Carcinoma of Esophagus →
- Advanced Cancer — all drugs for Advanced Cancer →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 75, any sex, with Small Cell Carcinoma of Esophagus or Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the anti-tumor activity, safety and tolerance of toripalimab as monotherapy for patients with small cell esophageal cancer (SCCE), and to explore the potential biomarkers for this treatment.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade.
Yang J, Liu X, Cao S, Dong X, et al · · 2020 · cited 134× · PMID 33014854 · DOI 10.3389/fonc.2020.01727 -
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.
Pansy K, Uhl B, Krstic J, Szmyra M, et al · · 2021 · cited 87× · PMID 34948104 · DOI 10.3390/ijms222413311 -
Programmed cell death-ligand 2: A neglected but important target in the immune response to cancer?
Solinas C, Aiello M, Rozali E, Lambertini M, et al · · 2020 · cited 61× · PMID 32622310 · DOI 10.1016/j.tranon.2020.100811 -
Immune Checkpoint Inhibitors in Esophageal Cancers: are we Finally Finding the Right Path in the Mist?
Vivaldi C, Catanese S, Massa V, Pecora I, et al · · 2020 · cited 21× · PMID 32121290 · DOI 10.3390/ijms21051658 -
Radiotherapy for small cell carcinoma of the esophagus: outcomes and prognostic factors from a retrospective study.
Chen B, Yang H, Ma H, Li Q, et al · · 2019 · cited 17× · PMID 31752922 · DOI 10.1186/s13014-019-1415-9 -
S-1 plus apatinib followed by salvage esophagectomy for irinotecan-refractory small cell carcinoma of the esophagus: A case report and review of the literature.
Zhang C, Yu GM, Zhang M, Wu W, et al · · 2020 · cited 6× · PMID 32011517 · DOI 10.1097/md.0000000000018892 -
[Research Progress of Immunotherapy and Prognostic Markers in Small Cell Lung Cancer].
Wang Q, Peng W, Jiang M, Wu L. · · 2020 · cited 5× · PMID 32102135 · DOI 10.3779/j.issn.1009-3419.2020.03.08 -
A Retrospective Study of 52 Patients With Primary Small Cell Carcinoma of the Esophagus Treated With Radical Surgery.
Fan N, Wang Z, Huang Y, Tan Z, et al · · 2021 · cited 4× · PMID 34155924 · DOI 10.1177/10732748211027147
Verify or expand the search:
- PubMed search for NCT03811379
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Toripalimab
Trials testing the same drug.
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07423078 — Window of Opportunity in Preserving Laryngeal Function Trial · Phase 2 · recruiting
- NCT07480733 — Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors · Phase 2 · not yet recruiting
- NCT07320963 — Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma. · Phase 1, PHASE2 · not yet recruiting
- NCT07469956 — Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancre · Phase 2 · not yet recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03811379 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 23 January 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03811379.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing